Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline weight-loss result has sent its shares into a sharp decline. The stock ...

Novo Nordisk failed to impress the market with late-stage clinical trial data for CagriSema, an anti-obesity candidate, but it has more potential gems in its pipeline. Novo Nordisk and Eli Lilly ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

While the Danish drugmaker’s sales for its blockbuster products remain strong, Novo took a hit on the stock market late last year when its GLP-1 treatment CagriSema fell short of expectations during ...

DiveWire guarantees visibility for your news announcements through instant distribution to BioPharma Dive’s audience and its 176,000 newsletter subscribers for 21 days.

BUK bilong Pikinini (BbP) marked a significant milestone on April 8, in its mission to provide quality early childhood education to children across Papua New Guinea, celebrating its 18th birthday at a ...